JP2018522540A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522540A5
JP2018522540A5 JP2017563165A JP2017563165A JP2018522540A5 JP 2018522540 A5 JP2018522540 A5 JP 2018522540A5 JP 2017563165 A JP2017563165 A JP 2017563165A JP 2017563165 A JP2017563165 A JP 2017563165A JP 2018522540 A5 JP2018522540 A5 JP 2018522540A5
Authority
JP
Japan
Prior art keywords
seq
sequence
sequences
light chain
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017563165A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522540A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/053095 external-priority patent/WO2016193872A2/en
Publication of JP2018522540A publication Critical patent/JP2018522540A/ja
Publication of JP2018522540A5 publication Critical patent/JP2018522540A5/ja
Pending legal-status Critical Current

Links

JP2017563165A 2015-06-05 2016-05-26 骨形成タンパク質９（ｂｍｐ９）を標的とする抗体およびそれらのための方法 Pending JP2018522540A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2015/080887 2015-06-05
CN2015080887 2015-06-05
PCT/IB2016/053095 WO2016193872A2 (en) 2015-06-05 2016-05-26 Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor

Publications (2)

Publication Number Publication Date
JP2018522540A JP2018522540A (ja) 2018-08-16
JP2018522540A5 true JP2018522540A5 (cg-RX-API-DMAC7.html) 2019-06-06

Family

ID=56096674

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017563165A Pending JP2018522540A (ja) 2015-06-05 2016-05-26 骨形成タンパク質９（ｂｍｐ９）を標的とする抗体およびそれらのための方法

Country Status (25)

Country Link
US (2) US10047155B2 (cg-RX-API-DMAC7.html)
EP (1) EP3303387A2 (cg-RX-API-DMAC7.html)
JP (1) JP2018522540A (cg-RX-API-DMAC7.html)
KR (1) KR20180014714A (cg-RX-API-DMAC7.html)
CN (1) CN107614526A (cg-RX-API-DMAC7.html)
AR (1) AR104906A1 (cg-RX-API-DMAC7.html)
AU (1) AU2016273028B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017021484A2 (cg-RX-API-DMAC7.html)
CA (1) CA2982237A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017002705A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017011512A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170554A (cg-RX-API-DMAC7.html)
EA (1) EA201792561A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP17080733A (cg-RX-API-DMAC7.html)
HK (1) HK1249537A1 (cg-RX-API-DMAC7.html)
IL (1) IL254837A0 (cg-RX-API-DMAC7.html)
MX (1) MX2017015690A (cg-RX-API-DMAC7.html)
PE (1) PE20180041A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017502020A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201707815RA (cg-RX-API-DMAC7.html)
TN (1) TN2017000417A1 (cg-RX-API-DMAC7.html)
TW (1) TW201716438A (cg-RX-API-DMAC7.html)
UY (1) UY36706A (cg-RX-API-DMAC7.html)
WO (1) WO2016193872A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201805721B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
CN106994181A (zh) * 2017-03-10 2017-08-01 上海交通大学医学院附属第九人民医院 Bmp9在制备延缓肝纤维化药物中的应用
CN107760779B (zh) * 2017-11-03 2020-10-16 中国医学科学院阜外医院 肺动脉高压相关的突变型bmp9基因及其应用
KR20220119424A (ko) 2019-12-20 2022-08-29 노파르티스 아게 인테그린 억제제를 사용한 간 질환의 조합 치료
WO2022101853A1 (en) 2020-11-16 2022-05-19 Novartis Ag Method of determining liver fibrosis
KR102780923B1 (ko) * 2021-10-22 2025-03-17 고려대학교 산학협력단 Bmp 유래 신규 펩타이드 및 이의 용도
PE20251175A1 (es) 2022-05-31 2025-04-23 Pfizer Anticuerpos anti-bmp9 y metodos de uso de los mismos
CN115040638A (zh) * 2022-06-14 2022-09-13 上海市东方医院（同济大学附属东方医院） Bmp9在制备mafld、nash、nash相关肝纤维化/肝硬化的药物中的用途
CN116058335B (zh) * 2022-11-25 2025-07-25 中国医学科学院阜外医院 一种自发强直性脊柱炎模型的构建方法和应用
CN116115736A (zh) * 2022-12-09 2023-05-16 上海交通大学医学院附属瑞金医院 一种bmp9在制备抑制成骨细胞衰老的制剂或药物中的应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
EP0318554B2 (en) 1987-05-21 2005-01-12 Micromet AG Targeted multifunctional proteins
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU643109B2 (en) 1990-12-14 1993-11-04 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
AU652472B2 (en) 1991-06-25 1994-08-25 Genetics Institute, Llc BMP-9 compositions
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
ATE427968T1 (de) 1992-08-21 2009-04-15 Univ Bruxelles Immunoglobuline ohne leichtkette
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
HUT76369A (en) 1994-07-29 1997-08-28 Smithkline Beecham Corp Novel soluble protein compounds
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6423501B2 (en) 1996-12-13 2002-07-23 Beth Israel Deaconess Medical Center Calcium-independent negative regulation by CD81 of receptor signaling
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6034062A (en) 1997-03-13 2000-03-07 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-9 compositions and their uses
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
WO1998056906A1 (en) 1997-06-11 1998-12-17 Thoegersen Hans Christian Trimerising module
ATE386802T1 (de) 1997-06-12 2008-03-15 Novartis Int Pharm Ltd Künstliche antikörperpolypeptide
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
PT1144607E (pt) 1999-07-20 2009-04-22 Morphosys Ag Novos métodos para apresentar (poli)peptídeos/ proteínas em partículas bacteriofágicas através de ligações dissulfureto
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
EP1803730A1 (en) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
US7943129B2 (en) 2000-05-26 2011-05-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
CA2412494C (en) 2000-06-22 2012-10-23 Genentech, Inc. Agonist anti-trk-c monoclonal antibodies
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
WO2002092780A2 (en) 2001-05-17 2002-11-21 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
WO2003048731A2 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Antibody categorization based on binding characteristics
US20030157579A1 (en) 2002-02-14 2003-08-21 Kalobios, Inc. Molecular sensors activated by disinhibition
US7335478B2 (en) 2002-04-18 2008-02-26 Kalobios Pharmaceuticals, Inc. Reactivation-based molecular interaction sensors
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US7816497B2 (en) 2002-10-30 2010-10-19 University Of Kentucky Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
WO2004072266A2 (en) 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
US7745585B2 (en) 2003-09-02 2010-06-29 Boehringer Ingelheim International Gmbh Antibodies to interleukin-like epithelial-mesenchymal transition inducer (ILEI)
SG166768A1 (en) 2003-12-23 2010-12-29 Rinat Neuroscience Corp Agonist anti-trkc antibodies and methods using same
EP2990053A1 (en) 2004-01-20 2016-03-02 KaloBios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
EP1571159A1 (en) 2004-03-04 2005-09-07 Bayerische Julius-Maximilians-Universität Würzburg Mutein of a bone morphogenetic protein and use thereof
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
PT1781814E (pt) 2004-08-10 2010-04-12 Cardiff Biolog Ltd Métodos e kit para o prognóstico do cancro da mama
JP4696237B2 (ja) 2005-03-03 2011-06-08 国立大学法人 岡山大学 糖尿病性腎症の治療用医薬組成物
UA94060C2 (ru) 2005-09-07 2011-04-11 Эмджен Фримонт Инк. Моноклональное антитело, которое специфически связывает alk-1
EP1946765A4 (en) 2005-09-22 2009-10-21 Keiichi Fukuda MEANS FOR THE TREATMENT OF ANGIOGENESIS-RELATED DISEASES WITH CHROMDROMODULIN-I AS AN ACTIVE AGENT
CN1844391A (zh) 2006-04-26 2006-10-11 嘉兴波亿生物科技开发有限公司 人骨形态发生蛋白9重组蛋白质核苷酸序列及生产方法和用途
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
EP1873157A1 (en) 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
US8088895B2 (en) 2006-10-18 2012-01-03 Chemocentryx, Inc. Antibodies that bind CXCR7 epitopes
US8642031B2 (en) * 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
EP3181580A1 (en) * 2006-11-02 2017-06-21 Acceleron Pharma Inc. Alk1 receptor and ligand antagonists and uses thereof
JP2008225463A (ja) 2007-02-14 2008-09-25 Asahi Kasei Chemicals Corp 積層光学フィルム
CA2681177C (en) 2007-03-19 2019-08-20 National Research Council Of Canada Antagonists of ligands and uses thereof
WO2008151078A1 (en) 2007-06-01 2008-12-11 Wyeth Methods and compositions for modulating bmp-10 activity
CA2724525A1 (en) 2008-05-15 2009-11-19 Acceleron Pharma, Inc. Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
WO2010126169A1 (ja) * 2009-04-30 2010-11-04 協和発酵キリン株式会社 Alk1阻害剤を有効成分とする血管障害を抑制するための医薬組成物
WO2010128158A1 (en) 2009-05-08 2010-11-11 Novartis Ag Diagnostic biomarkers for fibrotic disorders
US20160228509A9 (en) * 2009-05-08 2016-08-11 Novartis Ag Diagnostic BioMarkers for Fibrotic Disorders
RU2013104029A (ru) 2010-08-20 2014-09-27 ВАЙЕТ ЭлЭлСи Сконструированные остеогенные белки
CN103476429B (zh) 2010-09-03 2016-08-24 施特姆森特克斯股份有限公司 新型调节剂及使用方法
FR2971250A1 (fr) 2011-02-07 2012-08-10 Univ Nantes Anticorps anti-gb3 utiles dans le traitement des maladies associees a l'angiogenese
EP2809335A4 (en) 2012-02-02 2015-10-28 Acceleron Pharma Inc ALK1 ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF NIERENZELLENKARZINOMEN
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
KR101933990B1 (ko) 2012-05-02 2018-12-31 심포젠 에이/에스 인간화 ｐａｎ­ｈｅｒ 항체 조성물
CN103387605B (zh) 2012-05-08 2018-06-12 复旦大学 一种rtn4b多肽、其单抗、产生单抗的杂交瘤细胞株及他们的制备与应用
HK1209769A1 (en) * 2012-07-02 2016-04-08 Kyowa Hakko Kirin Co., Ltd. Therapeutic agent for anemia including renal anemia and cancer-induced anemia which contains anti-bmp9 antibody as active ingredient
FR2993278B1 (fr) 2012-07-13 2016-02-19 Coatex Sas Utilisation d'un polymere peigne pour preparer une suspension contenant du carbonate de calcium et presentant une sensibilite a la temperature reduite.
WO2014051109A1 (ja) 2012-09-28 2014-04-03 協和発酵キリン株式会社 抗ヒトｂｍｐ９抗体および該抗体を有効成分とする異所性骨化疾患の治療剤
CN105899225A (zh) * 2013-10-25 2016-08-24 阿塞勒隆制药公司 用于治疗纤维化疾病的内皮联蛋白肽

Similar Documents

Publication Publication Date Title
JP2018522540A5 (cg-RX-API-DMAC7.html)
JP2024150751A5 (cg-RX-API-DMAC7.html)
JP2018535650A5 (cg-RX-API-DMAC7.html)
JP7654346B2 (ja) 多重特異性抗体およびその使用
JP2018502060A5 (cg-RX-API-DMAC7.html)
JP2018516537A5 (cg-RX-API-DMAC7.html)
TW201124427A (en) IL-1 binding proteins
JP2017531642A5 (cg-RX-API-DMAC7.html)
KR20230016186A (ko) 갈렉틱-3 차단에 의한 염증성 질환의 치료 방법
KR20150131360A (ko) ＴＮＦα에 대해 지시된 이원 특이적 결합 단백질
JP2011528902A5 (cg-RX-API-DMAC7.html)
JP2012504955A5 (cg-RX-API-DMAC7.html)
MX2014008101A (es) Proteinas de union especificas duales dirigidas contra il-13 y/o il-17.
JP2016538876A5 (cg-RX-API-DMAC7.html)
CN112165974B (zh) 乙型肝炎抗体
AU2014248636B2 (en) Humanized anti-N2 antibodies
JP2010520290A5 (cg-RX-API-DMAC7.html)
CN110612309A (zh) 用于降低免疫原性的方法和组合物
JPWO2019209995A5 (cg-RX-API-DMAC7.html)
WO2017059813A1 (zh) 抗乙肝表面抗原的抗体及其用途
JP2023516195A (ja) Ｃ１９ ｃ３８二特異性抗体
TW202342095A (zh) 用於治療和預防ｃｏｖｉｄ—１９之組成物
CN116234577A (zh) 用于治疗和预防covid-19的sars-cov-2抗体
JP2020505350A5 (cg-RX-API-DMAC7.html)
JP2021520854A (ja) 黄熱を処置するための方法および組成物